Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Trading

<< Previous

Bullboard Posts

Next >>

Comment by whisky11on Apr 16, 2021 10:45am

131 Views

Post# 33010621

RE:Trading

Raiders11]Over 3 million on the ask up to 9 cents,don't get mad Whiskey but to many traders want to sell,need some major news,not enough short position for a squeeze,I think most got out when the halt was lifted,I'm still holding

whisky11: I bought some half an hour ago for 7 cents.
I buy when there is no volume.
Nobody can time the market, most of the time when you buy on deep it's still may go deeper.
Company is good ,stock price is too low .
They're going to be good news namely the date of phase 1.
About shorters I don't think they could cover after halt was lifted, stock price skyrockets very fast.

<< Previous

Bullboard Posts

Next >>

Infield Minerals to acquire Kings Canyon Gold Property